Business News • PR NewsWire • BerGenBio Presents Key Results From PhII Programme With Selective AXL Inhibitor Bemcentinib at DNB's 9th Annual Nordic Healthcare Conference

BerGenBio Presents Key Results From PhII Programme With Selective AXL Inhibitor Bemcentinib at DNB's 9th Annual Nordic Healthcare Conference

BerGenBio Presents Key Results From PhII Programme With Selective AXL Inhibitor Bemcentinib at DNB's 9th Annual Nordic Healthcare Conference

- Bemcentinib proof of concept clinical data as monotherapy and in combination confirms focus on lung cancer & leukaemia - AXL biomarker correlation supports bemcentinib's proposed MoA, potential for Companion Diagnostic - Significant milestones expected over next 12 months BERGEN,...

View More : https://www.prnewswire.com:443/news-releases/bergenbio-presents-key-results-from-phii-programme-with-selective-axl-inhib...

Releted News by prnewswire

2018 Seoul International Invention Fair: Majority of Awards Given to Safety and Hygiene Inventions

Leading Asian Integrated Security Exhibition -- SECON 2019 To Be Held in March Next Year

RecRight Video Interviews Now Live on SAP® App Center

Changes in Volvo's Management

Ministry of Investment and International Cooperation: Agreements Worth $3.5 Billion Signed on the Margins of the Africa 2018 Forum